Xiangrong Song

Co-Founder & CEO at WestGene Biopharma

Speaker

National-level Young Talent   Professor and Doctoral Supervisor at Sichuan University Ph.D. in Pharmacology    Postdoctoral training in Biology. Visiting Professor in Nanomedicine and Immunology at Harvard Medical School.

Co-Founder and General Manager. Dr. Xiangrong Song holds several positions and titles at the national and provincial levels, including committee member of the Nanobiotechnology Branch of the China Medicinal Biotechnology Association, committee member of the Nucleic Acid Vaccine Branch of the China Association for Vaccine, committee member of the Academic Committee of the Key Laboratory for Comprehensive Evaluation of Generic and New Drug and Pharmaceutical Excipient under the National Medical Products Administration, vice president of the Sichuan Association of Medical Communications, and more. She also serves as an editorial board member for six SCI journals, including Sig Transduct Target Ther (IF 38.104), Eur J Pharm Sci (IF 5.112) and Nat Rev Drug Discov (IF=64.797) Chinese edition, Acta Pharm Sin B (IF 14.903), Chin Chem Lett (IF 8.455), and Asian J Pharm Sci (IF 9.273).

Dr. Xiangrong Song has been involved in innovative drug development based on targeted delivery for more than 20 years. She has made extensive breakthroughs in the key technologies underlying mRNA drugs and holds core patents in mRNA sequence, delivery vectors and intelligent manufacturing devices. She has filed more than 60 patent applications (including 5 international patents) and has been granted more than 20 patents (including 1 U.S. patent). She has led more than 30 national and provincial research projects, including major projects funded by the National Science and Technology Major Project and the National Natural Science Foundation of China. She has published more than 100 SCI papers in prestigious journals such as Nature, Nat Comm, and Sci Adv, including more than 20 as first author or corresponding author, with an impact factor of more than 10. Under her leadership, three mRNA drug candidates have entered international clinical trials and a novel nanoadjuvant has been approved for Emergency Use Authorization (EUA) in China.

Dr. Xiangrong Song has received several prestigious national and provincial awards, including the Distinction Award at the National Disruptive Technology Innovation Competition(2022), the Gold Prize at the 1st West China Women's Science and Technology Innovation Competition(2023), the First Prize of the China Medical Association of Minorities Science and Technology Award (2019), and the Third Prize of the Chinese Medical Association Science and Technology Award (2020). Her rich practical experience in drug translation and development contributes to her achievements in the field.